组蛋白去乙酰化酶抑制剂增强乳腺癌细胞毒性并保留脂肪干细胞创面愈合功能
研究将低剂量紫杉醇(0.1 μM)与组蛋白去乙酰化酶抑制剂(HDACi)SAHA或TSA联用于三阴性乳腺癌细胞MBA-MB-231与人脂肪来源干细胞(hASCs),并以标准剂量紫杉醇(1.0 μM)为对照。结果显示联合治疗维持对乳腺癌细胞的细胞毒性并保留hASC活性,HDACi未增加hASC凋亡,且经HDACi处理的hASC间接共培养可增强损伤成纤维细胞的迁移与创面愈合。
要点
- HDACi联合低剂量紫杉醇可维持对乳腺癌细胞的细胞毒性并保留hASC活性。
- HDACi对hASC基因表达呈选择性抗炎作用并下调促凋亡基因FAS,未增加hASC凋亡。
- 经HDACi处理的hASC可间接促进损伤成纤维细胞迁移,提示有助于重建术后创面愈合。
核心结论
- HDACi联合低剂量紫杉醇在增强对乳腺癌细胞细胞毒性的同时保留hASC活性,并在成纤维细胞划痕实验中观察到迁移改善。
- 作者提出在紫杉类化疗方案中加入HDACi可能改善重建术后的肿瘤学结果与创面愈合结局。
研究设计与样本
- 体外细胞实验:三阴性乳腺癌细胞MBA-MB-231与经机构审查委员会批准的临床来源hASCs。
- 干预分组:标准治疗剂量紫杉醇1.0 μM,或低剂量紫杉醇0.1 μM联合HDACi(suberoylanilide hydroxamic acid或trichostatin A)。
- 检测方法:MTT法测细胞活力、qRT-PCR测基因表达、annexin V法测凋亡、成纤维细胞划痕实验测愈合与迁移。
主要发现
- 联合HDACi与低剂量紫杉醇维持对乳腺癌细胞的细胞毒性并保留脂肪干细胞活力。
- HDACi对hASC基因表达呈选择性抗炎作用,并降低促凋亡基因FAS表达。
- HDACi治疗未增加hASCs内的相对凋亡。
- 划痕实验显示,与经HDACi处理的hASCs间接共培养的损伤成纤维细胞创面愈合增强。
临床怎么用
- 提示紫杉类化疗联合HDACi可能兼顾乳腺癌细胞杀伤与脂肪移植、重建所需hASC的创面愈合功能。
- 结果来自体外实验,临床用于乳腺癌切除后重建决策前仍需进一步验证。
局限性
- 为体外细胞实验,仅使用MBA-MB-231细胞系与临床来源hASCs,未涉及动物模型或临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Paclitaxel improves the oncologic response of breast cancer resections; however, it may negatively affect the wound-healing potential of human adipose-derived stem cells (hASCs) for fat grafting and reconstructive surgery. Histone deacetylase inhibitors (HDACis) modify the epigenetic regulation of gene expression and stabilize microtubules similarly to paclitaxel, thus, creating a synergistic mechanism of cell cycle arrest. We aim to combine these drugs to enhance cytotoxicity towards breast cancer cells, while preserving the wound-healing function of hASCs for downstream reconstructive applications. METHODS: Triple negative breast cancer cells (MBA-MB-231) and hASCs (institutional review board-approved clinical isolates) were treated with a standard therapeutic dose of paclitaxel (1.0 μM) or with low-dose paclitaxel (0.1 μM) combined with the HDACi suberoylanilide hydroxamic acid or trichostatin A. Cell viability, gene expression, apoptosis, and wound-healing/migration were measured via methylthiazol tetrazolium assay, quantitative real-time polymerase chain reaction, annexin V assay, and fibroblast scratch assay, respectively. RESULTS: Combined HDACi and low-dose paclitaxel therapy maintained cytotoxicity towards breast cancer cells and preserved adipose-derived stem cell viability. Histone deacetylase inhibitor demonstrated selective anti-inflammatory effects on adipose-derived stem cell gene expression and decreased expression of the proapoptotic gene FAS. Furthermore, HDACi therapy did not increase relative apoptosis within hASCs. A scratch assay demonstrated enhanced wound healing among injured fibroblasts indirectly co-cultured with HDACi-treated hASCs. CONCLUSIONS: Combining HDACi with low-dose paclitaxel improved cytotoxicity towards breast cancer cells and preserved hASC viability. Furthermore, enhanced wound healing was observed by improved migration in a fibroblast scratch assay. These results suggest that the addition of HDACi to taxane chemotherapy regimens may improve oncologic results and wound-healing outcomes after reconstructive surgery.
引用
- Koko KR, Chang S, Hagaman AL, et al. Histone Deacetylase Inhibitors Enhance Cytotoxicity Towards Breast Tumors While Preserving the Wound-Healing Function of Adipose-Derived Stem Cells. Ann Plast Surg. 2017. PMID: 28489652. doi:10.1097/SAP.0000000000001066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。